Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of hepatitis b virus related compensated cirrhosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
• Treatments: Entecavir; Tenofovir

Criteria

Inclusion Criteria:

1. Positive hepatitis b surface antigen or hepatitis b virus DNA > 0.5 year;

2. Age from 18 to 65 years old;

3. Hepatitis b virus DNA positive;

4. Cirrhosis or portal hypertension is found through ultrasonography, computed tomography or magnetic resonance imaging;

5. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

Exclusion Criteria:

1. Complications of decompensated cirrhosis: ascites, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, etc;

2. Other active liver diseases;

3. Hepatocellular carcinoma or other malignancy;

4. Pregnancy or lactation;

5. Human immunodeficiency virus infection or congenital immune deficiency diseases;

6. Severe diabetes, autoimmune diseases;

7. Other important organ dysfunctions;

8. Using glucocorticoid;

9. Patients can not follow-up;

10. Investigator considering inappropriate.